Platelet aggregating activity in the plasma of patients with established thrombosis.
This study examines the incidence and significance of novel plasma derived platelet aggregating activity (PAA) in 190 consecutive patients admitted to the medical wards of a general hospital. Seventy five patients (39%) demonstrated this activity. The incidence was highest in patients with a history of thrombosis (52%) or in those with a heightened thrombotic tendency, for example, patients with diabetes or hypertension. In contrast, platelet aggregating activity was observed in six out of 62 patients (approximately 10%) in whom a current or past medical history of thrombosis could not be elicited and in only two out of 72 healthy volunteers examined (3%). A high frequency of PAA was also noted in a small group of patients with idiopathic thrombocytopenia and patients who had previously received platelet transfusions. In these patients, this activity presumably reflects the presence of antiplatelet antibodies. A good correlation between the presence of plasma derived platelet aggregating activity and the phenomenon of spontaneous platelet aggregation was observed. The platelet aggregating activity was not heparin dependent, but was completely abolished by EDTA (5 mM) and benzamidine (8 mM), or by pretreating the platelets with aspirin. A synergistic response was observed with subaggregatory concentrations of thrombin and adrenalin. Our results suggest that the presence of this platelet aggregating activity may provide a marker for vascular thrombosis. Furthermore we postulate that this plasma derived activity may be partly responsible for platelet hyperactivity previously observed in patients with thromboembolic disorders.
Jackson
S P
SP
Department of Medicine, Monash Medical School, Prahran, Vic, Australia.
Salem
H H
HH
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000494:pharmacology; D001550:Benzamidines / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000032:analysis; D004492:Edetic Acid / Q000494:pharmacology; D006801:Humans; D008875:Middle Aged; D010972:Platelet Activating Factor; D010974:Platelet Aggregation / Q000187:drug effects; D013921:Thrombocytopenia / Q000097:blood / Q000188:drug therapy; D013927:Thrombosis / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors
D001550:Benzamidines; D001779:Blood Coagulation Factors; D010972:Platelet Activating Factor; D004492:Edetic Acid; D001241:Aspirin